USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: PLANET BIOTECHNOLOGY, INC.
Address: 25571 CLAWITER RD
HAYWARD, CA 94545-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,823,991.00 12
SBIR Phase II $13,210,543.00 5
STTR Phase I $145,060.00 1

Award List:

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: USDA
Principal Investigator: Keith Wycoff
Award Amount: $70,000.00

A SPLIT-SELECTABLE MARKER FOR MULTIGENE TRANSFORMATIONS

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lloyd M. Yu
Award Amount: $100,000.00
Abstract:
DESCRIPTION: We will adapt fragment-complementation technology, originally developed for the investigation of protein-protein interactions, to engineer a new type of selectable marker and so facilitate selection of transformed, green plants expressing multi-subunit therapeutic… More

BOTULINUM TOXIN PLANTIBODIES

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith L. Wycoff
Award Amount: $104,520.00
Abstract:
DESCRIPTION (provided by applicant): Our overall goal in this project is to make available inexpensive neutralizing antibodies against Botulinum neurotoxin in large quantity. We will combine our experience in producing functional antibodies in transgenic plants with three neutralizing antibodies… More

Botulinum Toxin Plantibodies

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency / Branch: DOD / CBD
Principal Investigator: Keith Wycoff, Research Director
Award Amount: $69,808.00
Abstract:
Our overall goal in this project is to make available inexpensive neutralizing antibodies against Botulinum neurotoxin (BoNT) in large quantity, using transgenic plants. Dr. James Marks (UC San Francisco School of Medicine) has identified murine and humansingle chain Fv (scFv) that bind… More

Immunotherapy for Pulmonary Anthrax

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith L. Wycoff
Award Amount: $109,500.00
Abstract:
DESCRIPTION (provided by applicant): Our overall goal in this project is to make available in large quantity an inexpensive recombinant protein that protects against the cellular toxicity associated with inhalational (pulmonary) anthrax. We will combine our experience in producing functional… More

Botulinum Toxin Plantibodies

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency / Branch: DOD / CBD
Principal Investigator: Keith Wycoff, Research Director
Award Amount: $729,832.00
Abstract:
The primary goals of this Phase II application are to successfully manufacture pilot-scale quantities of neutralizing anti-botulinum toxin antibodies in plants, and to complete preclinical studies with these antibodies. Our collaborator, Dr. James D. Mar

Amplicon Plus for High-Level Expression of Therapeutic Proteins in Plants

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF SOUTH CAROLINA
Principal Investigator: Keith L. Wycoff
Award Amount: $145,060.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Molecular farming is an emerging biotechnology in which plants are used as "biofactories" to produce beneficial bio-products, such as antibodies, enzymes or edible vaccines. Plants provide a safe and low-cost alternative for production of Pharmaceuticals and… More

Botulinum Toxin Plantibodies

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Keith L. Wycoff
Award Amount: $5,093,489.00
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective countermeasure to defend the American public from a bioterrorist attack by botulinum toxin. We aim to be the manufacturer of an antibody or antibody… More

Novel Therapy for Pulmonary Anthrax

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Keith L. Wycoff
Award Amount: $3,589,261.00
Abstract:
DESCRIPTION (provided by applicant): We have shown that a plant-produced recombinant protein derived from a human anthrax toxin receptor protein and human IgG (an immunoadhesin), neutralizes anthrax lethal toxin in cell culture assays. In this project we will show the effectiveness of this… More

Optimization of Codon-Pair Usage to Maximize Protein Expression in Plants

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith Wycoff
Award Amount: $145,410.00
Abstract:
DESCRIPTION (provided by applicant): Inexpensive therapeutic recombinant proteins, such as monoclonal antibodies, can be produced using plants as biofactories. For reasons that are unclear, the yield of antibodies has been low in practical agricultural c rops, such as tobacco. We hypothesize that… More

Improved Method for Purification of Therapeutic Proteins from Plants

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith Wycoff
Award Amount: $109,964.00
Abstract:
DESCRIPTION (provided by applicant): Transgenic plants are a promising platform for the large-scale production of antibodies and other therapeutic proteins for treating serious and life-threatening conditions. The advantages of using plants, rather than ge netically modified animal cells in… More

An Anti-Cancer Immunoadhesin Made in Plants

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith Wycoff
Award Amount: $159,450.00
Abstract:
DESCRIPTION (provided by applicant): The growth and metastasis of tumors depends, to a large extent, on the development of new blood vessels to supply food and oxygen to rapidly growing and dividing cells. Proteins involved in angiogenesis are attractive t argets for new cancer therapeutics. One… More

An Immunoadhesin Therapy for Gastrointestinal Anthrax

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith Wycoff
Award Amount: $159,096.00
Abstract:
DESCRIPTION (provided by applicant): The development of anthrax countermeasures has focused almost exclusively on the perceived threat of inhalational anthrax. However, preparing a sufficiently fine powder of Bacillus anthracis spores for aerosol distribut ion requires a high degree of technical… More

Novel Therapy for Pulmonary Anthrax

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Keith Wycoff
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant):  Planet Biotechnology Inc. (PBI) is developing a therapeutic recombinant protein, PBI-220, that neutralizes anthrax toxin in vitro and protects against inhalational anthrax in vivo. PBI uses transgenic plants as an innovative, economical and flexible… More

Maximizing Expression of Immunoglobulins in Plants

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: James Maclean
Award Amount: $797,961.00
Abstract:
DESCRIPTION (provided by applicant): Planet Biotechnology Inc. (PBI) has pioneered methods for the production of functional therapeutic antibodies and immunoadhesins in transgenic tobacco. For reasons that are unclear, the yield of antibodies in transg enic plants has generally been low, with… More

Plant-Made Nanobodies for Botulism Treatment

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith Wycoff – 510-887-1461
Award Amount: $236,847.00
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective therapeutic that can reverse the paralytic symptoms of botulism. Success in achieving this goal could savecountless lives in the event of a… More

An immunoadhesin for treatment of hypercholesterolemia

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith Wycoff – 510-887-1461
Award Amount: $282,629.00
Abstract:
DESCRIPTION (provided by applicant): In this project we propose producing, and testing in vivo, a recombinant protein that should sustainably reduce plasma low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9),a protein secreted in the liver, plays a key… More

Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith Wycoff – 510-887-1461
Award Amount: $276,767.00
Abstract:
DESCRIPTION (provided by applicant): Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism by which therapeutic monoclonal antibodies (mAbs) kill tumor cells. However, killing by current therapeutic IgG mAbs is not optimal. InefficientADCC provides a potential escape mechanism… More